From implementation to interoperation

Interoperability has been the buzz term for the past couple months as the Office of the National Coordinator for Health IT focuses on publishing its interoperability roadmap and other groups discuss the best way to achieve seamless information exchange.

Now that the majority of providers have implemented EHRs, it's time to get those systems linking to each other. Speaking at the recent Bipartisan Policy Center’s Health Innovation Initiative policy forum, John Hammergren, chairman, president and CEO of McKesson, said that interoperability is the most important thing to achieve to “get to where we need to go. We will not accomplish our mission if we cannot share the data.” He asked the audience to imagine a cell phone that only connected to the caller’s own service provider.

Citing McKesson’s participation in the CommonWell Alliance, Hammergren said it is a group of organizations that fundamentally understand the issue of connectivity at a granular level. “We’ve been trying to put a patchwork together of code hospital by hospital and physician by physician. The cost associated with that patchwork of interfaces is unsustainable. There’s a tremendous cost burden.”

He also said he looks forward to a more informed, educated and engaged consumer helping the industry transform the delivery system.

IT is the critical fuel to “help us transform and bend the cost curve. We have a tremendous opportunity before us. This is the most important time in healthcare.”

I think we'll see a lot more activity on this front in 2015.

Beth Walsh

Clinical Innovation + Technology editor

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.